Barcelona, Spain, Apr 19 (Prensa Latina) Spanish scientists have identified the type 1 serotonin receptor (HTR1) as a new therapeutic target for the treatment of Acute Myeloid Leukemia (AML), the specialized press reported today. The authors of the study, a team from Josep Carreras Leukemia Research Institute (IJC), demonstrated that leukemia cells express the HTR receptor on their surface.
According to specialists, the inhibition of this component leads to the destruction of leukemia cells and has minimal effect on healthy biological tissues.
This research demonstrates the importance of HTR1 in the development of this type of leukemia and identifies this group of receptors as a new therapeutic target in AML with prognostic value, experts said.
Acute myeloid leukemia is the most common in adults and accounts for 40 percent of all cases of blood cancer in the Western Hemisphere.
